Cryogenic Solutions Inc. (CYGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: G.P. who wrote (3699)	7/28/1999 9:29:00 AM
From: G.P.	Read Replies (1) of 4028

Wednesday July 28, 8:19 am Eastern Time Company Press Release Cryogenic Solutions Inc. Files Form 10-SB with SEC to Become a Reporting Company HOUSTON--(BUSINESS WIRE)--July 28, 1999--Cryogenic Solutions Inc. (OTC BB:CYGS) has voluntarily filed a Form 10-SB Registration Statement with the United States Securities And Exchange Commission. The Company will also send all required Material Requests to the National Association of Securities Dealers Inc. (NASD) in order to comply with the January 1999 SEC approved OTC Bulletin Board Eligibility Rule. ''We are eager to comply with all regulatory agencies as we pursue the development and commercialization of our ssDNA Expression Vector,'' said Lawrence Wunderlich, Vice President of Finance for CYGS. ''This signifies another important step in the growth of the Company. We are committed to building shareholder value.'' CYGS has exclusive rights to the ssDNA vector technology developed by Dr. Charles Conrad of InGene Inc. The ssDNA vector can synthesize sequence specific single strands of DNA in vivo with or without flanking regions. This ability makes the ssDNA vector a most promising technology for overcoming the delivery barrier to an effective antisense gene therapy. This release contains forward-looking statements and is made under the protections afforded by the Securities Litigation Reform Act of 1995. Anyone who does not understand the overall antisense biotechnology referenced in this document or the significance of the specific CYGS technology is discouraged from investing in this company. -------------------------------------------------------------------------------- Contact: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next